Soleno Therapeutics, Inc. $SLNO Holdings Lifted by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC boosted its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 25.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,577,777 shares of the company’s stock after acquiring an additional 527,777 shares during the quarter. Soleno Therapeutics accounts for about 2.3% of Avoro Capital Advisors LLC’s investment portfolio, making the stock its 16th largest holding. Avoro Capital Advisors LLC owned 4.80% of Soleno Therapeutics worth $174,258,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Wellington Management Group LLP increased its stake in Soleno Therapeutics by 272.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock valued at $156,298,000 after buying an additional 1,691,057 shares during the period. Perbak Capital Partners LLP acquired a new stake in Soleno Therapeutics during the third quarter valued at $351,000. F m Investments LLC grew its stake in Soleno Therapeutics by 40.9% in the third quarter. F m Investments LLC now owns 55,730 shares of the company’s stock valued at $3,767,000 after purchasing an additional 16,189 shares in the last quarter. Glenmede Investment Management LP grew its stake in Soleno Therapeutics by 20.5% in the third quarter. Glenmede Investment Management LP now owns 6,448 shares of the company’s stock valued at $436,000 after purchasing an additional 1,095 shares in the last quarter. Finally, Kennedy Capital Management LLC acquired a new position in Soleno Therapeutics in the 3rd quarter worth about $2,668,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on SLNO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Zacks Research lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. TD Cowen reduced their target price on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Wells Fargo & Company dropped their price target on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Finally, Wolfe Research set a $60.00 price target on shares of Soleno Therapeutics in a report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Soleno Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.85.

Soleno Therapeutics Stock Down 8.1%

Shares of NASDAQ:SLNO opened at $33.76 on Friday. Soleno Therapeutics, Inc. has a 12 month low of $32.63 and a 12 month high of $90.32. The company’s 50-day moving average price is $40.74 and its two-hundred day moving average price is $51.18. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The firm has a market cap of $1.74 billion, a P/E ratio of 146.79 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. As a group, research analysts forecast that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.

Soleno Therapeutics News Summary

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Recent operational data: Soleno reported quarterly results on Feb. 25 that beat consensus — $0.80 EPS vs. $0.64 estimate and revenue roughly $91.7M vs. ~$88.6M — a near‑term fundamental positive that may temper downside if litigation risk abates.
• Negative Sentiment: Class action filings allege Soleno misled investors about the integrity, safety and results of its DCCR Phase 3 program, citing the company’s Nov. 5, 2025 disclosures; the Hagens Berman notice is a representative filing. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Multiple national plaintiff firms (Robbins Geller, Schall, Kessler Topaz, Rosen, Glancy Prongay, Levi & Korsinsky, etc.) are actively soliciting clients and reminding investors of the May 5, 2026 lead‑plaintiff deadline, increasing the likelihood of consolidated litigation and potential settlement exposure. Deadline Approaching: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
• Negative Sentiment: Allegations across notices include claims of concealed safety issues, material misstatements/omissions about trial conduct and efficacy, and even charges of “sham” trials — outcomes that, if substantiated, could lead to regulatory inquiry, management distraction, legal costs and damages payments.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.